New clinical trials policy at FDA

被引：14
|
作者：
Vastag, Brian
机构：
来源：
NATURE BIOTECHNOLOGY | 2006年 / 24卷 / 09期
关键词：
D O I：
10.1038/nbt0906-1043
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
[No abstract available]
引用
收藏
页码：1043 / 1043
页数：1
相关论文
共 50 条
  • [31] US FDA streamlines safety reporting in clinical trials
    Reactions Weekly, 2011, 1356 (1) : 2 - 2
  • [32] FDA Proposes Guidance for Increasing Diversity in Clinical Trials
    Harris, Emily
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (07):
  • [33] FDA NEW DRUG APPROVAL POLICY - WHY
    PATTERSON, R
    GRAMMER, LC
    NEW ENGLAND AND REGIONAL ALLERGY PROCEEDINGS, 1985, 6 (04): : 379 - 380
  • [34] INVESTIGATIONAL NEW DRUGS - FDA REGULATORY POLICY
    GINZBURG, HM
    PEDIATRIC AIDS AND HIV INFECTION-FETUS TO ADOLESCENT, 1992, 3 (04): : 202 - 212
  • [35] Nanoparticles in Clinical Trials: Analysis of Clinical Trials, FDA Approvals and Use for COVID-19 Vaccines
    Namiot, Eugenia D.
    Sokolov, Aleksandr, V
    Chubarev, Vladimir N.
    Tarasov, Vadim V.
    Schioth, Helgi B.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (01)
  • [36] FDA AUDITS OF CLINICAL-STUDIES - POLICY AND PROCEDURE
    LISOOK, AB
    JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (04): : 296 - 302
  • [37] In dialogue with the NIH on clinical trials policy
    Wolfe, Jeremy M.
    NATURE HUMAN BEHAVIOUR, 2018, 2 (02): : 100 - 102
  • [38] PAs as principal investigators of FDA-regulated clinical trials
    Nalepinski, Colleen Elizabeth Gosa
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2023, 36 (06): : 40 - 42
  • [39] The FDA Initiative to Assure Racial and Ethnic Diversity in Clinical Trials
    Adashi, Eli Y.
    Cohen, I. Glenn
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2023, 36 (02) : 366 - 368
  • [40] In dialogue with the NIH on clinical trials policy
    Jeremy M. Wolfe
    Nature Human Behaviour, 2018, 2 : 100 - 102
12345